Mahak Sayyed’s Post

𝐓𝐡𝐞 𝐑𝐢𝐬𝐢𝐧𝐠 𝐃𝐞𝐦𝐚𝐧𝐝 𝐟𝐨𝐫 𝐈𝐦𝐩𝐨𝐭𝐞𝐧𝐜𝐞 𝐀𝐠𝐞𝐧𝐭𝐬: 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 The Global #Impotence_Agents_Market is projected to grow at a CAGR of around 6.8% during the forecast period, i.e., 2023-28. The market is poised for significant growth owing to the globally rising prevalence of ED (Erectile Dysfunction) owing to the increased burden of lifestyle diseases, such as atherosclerosis, hypertension, diabetes, obesity, depression, & stress, among other medical conditions, resulting in a growing demand for impotence agents. 𝐇𝐞𝐫𝐞'𝐬 𝐚 𝐠𝐥𝐢𝐦𝐩𝐬𝐞 𝐨𝐟 𝐰𝐡𝐚𝐭 𝐲𝐨𝐮'𝐥𝐥 𝐟𝐢𝐧𝐝 𝐢𝐧𝐬𝐢𝐝𝐞: ✅Market size and growth projections for 2023-2028 ✅Breakdown by product type (tablets, injections, etc.) ✅Analysis of key market segments (hospitals, pharmacies, etc.) ✅Impact of rising ED prevalence due to lifestyle diseases ✅Insights into prominent industry players 𝐆𝐞𝐭 𝐚 𝐂𝐨𝐦𝐩𝐥𝐢𝐦𝐞𝐧𝐭𝐚𝐫𝐲 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 (2024-30)- https://lnkd.in/gYMqQess 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬- Pfizer, Mylan, Novartis, Hikma Pharmaceuticals, AUROBINDO PHARMA LTD, AbbVie., Melinta Therapeutics, Bristol Myers Squibb, and many more. #health #healthcareindustry #ED #ErectileDysfunction #Healthcare #MarketResearch #Pharmaceuticals #marketresearchreports #marketanalysis #marketgrowth #industryanalysis #industrygrowth #consulting #marknteladvisors

The Levothyroxine Sodium market is poised for growth, with a value of $3.73 billion in 2023, projected to reach $3.90 billion in 2024 at a 4.4% CAGR. By 2028, it is expected to hit $4.65 billion. Key growth drivers include heightened awareness of hypothyroidism, expanded insurance coverage, and the introduction of cost-effective generics. Innovations like gel capsules, such as IBSA Pharma's Tirosint launched in 2023, are enhancing patient care. North America leads the market, while Asia-Pacific is set to grow rapidly due to rising healthcare investments. For more Info: https://lnkd.in/gH_BCZJ9 #HealthcareInnovation #Pharmaceuticals #ThyroidHealth #Levothyroxine #MarketGrowth #HealthCare #tbrc

The global market for Insulin Storage Cooler Bag was estimated to be worth US$ 252 million in 2023 and is forecast to a readjusted size of US$ 431 million by 2030 with a CAGR of 7.2% during the forecast period 20242030 #InsulinStorage #CoolerBagMarket #DiabetesCare #PortableInsulinBag #FixedInsulinStorage #HealthcareInnovation #GlobalHealth #MedicationSafety #PatientCare #MarketGrowth

𝐁𝐫𝐚𝐳𝐢𝐥 𝐈𝐧𝐬𝐮𝐥𝐢𝐧 𝐃𝐫𝐮𝐠𝐬 & 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟐 Brazil insulin drugs & delivery devices market size is projected to exhibit a growth rate (CAGR) of 1.44% during 2024-2032. The rising prevalence of diabetes, improvements in healthcare infrastructure, regulatory approvals and funding for advanced delivery devices, expanding geriatric population base, advancements in technology, and increased awareness about diabetes management represent some of the key factors driving the market. 𝐆𝐫𝐚𝐛 𝐚 𝐬𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/gQ4hAJUH 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬: ● 𝐑𝐢𝐬𝐢𝐧𝐠 𝐃𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞: Increasing incidence of type 2 diabetes due to lifestyle changes is driving demand for insulin products and advanced treatment options. ● 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬: Adoption of insulin pumps and CGMs is growing due to their effectiveness in managing diabetes and improving patient quality of life. ● 𝐆𝐨𝐯𝐞𝐫𝐧𝐦𝐞𝐧𝐭 𝐒𝐮𝐩𝐩𝐨𝐫𝐭: Government initiatives to improve access to diabetes care, including subsidies and awareness campaigns, are contributing to market growth. 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/gXJXqNP7 #insulindrugsdeliverydevicesbrazil #marketresearch #business #marketanalysis #markettrends #researchreport #marketreport #marketforecast #marketgrowth #businessinsights #industryanalysis #marketoutlook #growthprojections #marketstatistics #competitiveanalysis #trendanalysis #marketinsights #imarcgroup

The CAGR of the type 2 diabetes market is projected to be 7.7% from 2024 to 2031. The rise in the obese and overweight population and the increasing aging population are the major factors driving the growth of the type 2 diabetes market. Get comprehensive information on the type 2 diabetes market trends and growth. Click here: https://rb.gy/hmmbpq Key Players: Novo Nordisk, Sanofi, Lilly India, Merck,Boehringer Ingelheim and Many others #healthcare #MarketInsights #research #ResearchInsights #cmi #pharmaceuticalindustry #overweightpopulation

The Alarming Rise of Healthcare Costs: A Call to Action Healthcare's share of GDP is skyrocketing. We explore why costs are surging and the urgent need to control them before reaching unsustainable levels. Plus, we discuss possible solutions and the implications for autoimmune treatments. #HealthcareCost #GDPGrowth #Autoimmunity #CostControl #PublicHealth #HealthPolicy #AutoimmuneDisorders #Naltrexone #Peptides #HealthCareReform

The #Global #Chronic #Cough #Market, valued at USD 6.59 billion in 2022, is projected to reach USD 11.44 billion by 2029, growing at a CAGR of 8.2%. Chronic cough, persisting for at least eight weeks, stems from various causes such as #asthma, #postnasaldrip, and #gastroesophageal reflux #disease (GERD). It's also linked to long-term #tobacco #smoking and exposure to secondhand #smoke. With a significant global #health burden affecting approximately 10% of #adult populations #worldwide, chronic cough significantly impairs quality of life, making it a major health concern. Utilizing a bottom-up approach, the market #size estimation for chronic cough considers historical #data, current #trends, and future projections, incorporating competitive #dynamics within the #industry. 1. Cipla. 2. Reckitt 3. Hikma Pharmaceuticals 4. NeRRe Therapeutics Ltd 5. Merck Group #ChronicCough #RespiratoryHealth #HealthcareIndustry #GlobalHealth #MedicalResearch #QualityofLife #HealthcareTrends #DiseaseManagement #MarketAnalysis #HealthcareInsights

The Great Cholesterol Scam: Unveiling the Truth Behind Statins Recent revelations suggest that the cholesterol narrative has been manipulated, allegedly backed by sugar industry bribes to promote statin sales. This widespread medication only offers slight benefits, alongside severe side effects like muscle deterioration, liver damage, and nerve dysfunction. Nearly half of users discontinue statins due to these adverse effects. From my perspective, this issue reflects a broader pattern of misinformation in healthcare. The emphasis should be on transparency and patient well-being rather than pharmaceutical profits. Think about it: could the push for statins be more about financial gain than genuine health benefits? 📊 Studies reveal that 20% of statin users suffer serious injuries. ⚖️ Are we prioritizing the right treatments, or are we falling prey to profitable yet less effective solutions? 💭 Have you or someone you know experienced negative side effects from statins? Let's foster a conversation around informed choices and prioritize our health over industry profits. #healthcare #statins #pharmaceuticals #cholesterol #healthchoices

📈 Unlock 30% Savings on Market Research! Looking to stay ahead in the healthcare industry? The Business Research Company is offering up to 30% off on its market research reports for a limited time. Spotlight: Non-Insulin Therapies for Diabetes Market 🌐 The non-insulin therapies for diabetes market is projected to grow from $18.71 billion in 2023 to $19.98 billion in 2024 at a CAGR of 6.8%. Key drivers include rising diabetes prevalence, increased awareness, and government initiatives supporting diabetes management. By 2028, the market is expected to reach $26.14 billion, fueled by advancements in drug delivery, telemedicine, and combination therapies. With approximately 537 million adults affected globally and growing, non-insulin therapies that enhance glycemic control are essential. Top Segments to Watch: By Drug Class: GLP-1 Analogs, SGLT2 Inhibitors, etc. By Administration Route: Oral, Intramuscular By Distribution Channel: Retail, Hospital, Online Pharmacy Claim Your Free Sample Report Today! 📄 👉 Non-Insulin Therapies For Diabetes Market Report - https://lnkd.in/gUttiyic #tbrc #marketoverview #marketshare #diabetes #marketresearch #healthcare #insulin

🔬 Transforming Diabetes Diagnostics: A 70% Price Reduction in China! The future of glycated hemoglobin (HbA1c) testing in China is here, and it's revolutionary. With a groundbreaking 70% price reduction, HbA1c testing is now more accessible than ever. This pivotal change could reshape diabetes management and pave the way for better patient outcomes. 💡 What does this mean for the healthcare industry? # Affordable diagnostics for millions. # Improved early detection and monitoring for diabetes. # Greater opportunities for innovation in medical technologies. At Hzymes Biotechnology, we’re exploring the role of advanced enzymatic solutions in driving these changes. 👉 Dive into our latest blog to learn more about this transformation and its impact on the industry: 👇 Read the full article here: https://lnkd.in/gxUUS-7Z #IVD #DiabetesDiagnostics #HealthcareInnovation #HbA1c #Biotechnology #ChinaHealthcare